Compare Digital Realty Trust, Inc. (DLR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Neurocrine Biosciences Inc — how do they compare? Digital Realty Trust, Inc. trades at $176.26 (market cap $66.95B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Digital Realty Trust, Inc. is far larger — about 4.6× Neurocrine Biosciences Inc's market cap, and Digital Realty Trust, Inc. pays a 2.7% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DLR | NBIX | |
|---|---|---|
Market Cap | $66.95B | $14.60B |
Volume | 1,766,660 | 1,075,694 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $185.50 |
52-Week Low | $147.93 | $123.10 |
Typical Hold Time | 94 Days | 23 Days |
Enterprise Value | $85.67B | $14.61B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $176.07, down 4.65% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamental momentum, with Q2 2026 EPS beating expectations at $1.21 versus $0.4829, and revenue growth from $6.11B in 2025 to a projected $6.8B in 2026. Recent news highlights expansion in AI infrastructure, including a collaboration with Blackfuel and a new Los Angeles cable landing station, positioning the company to capitalize on data center demand.
The outlook for DLR is positive, driven by robust AI-driven demand and a record backlog, though high valuation multiples like a P/E of 88.03 pose a risk if growth slows. Analyst consensus is strongly bullish with a $222.35 price target, but investors face risks from significant capital expenditures and debt levels.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
